Fulcrum Therapeutics Starts Phase 3 Trial of Muscle Disorder Drug for COVID-19

Fulcrum Therapeutics has begun a phase 3 clinical trial in the U.S. of its investigational anti-inflammatory drug losmapimod for treatment of hospitalized COVID-19 patients.

The 400-patient trial will assess the proportion of patients who progress to death or respiratory failure by day 28 after receiving two daily doses for 14 days.

The Massachusetts drugmaker is currently developing the selective enzyme inhibitor as a treatment for facioscapulohumeral muscular dystrophy, which causes muscle weakness and wasting.